
    
      This is a sham-controlled, randomized trial for patients with MDD to identify the effects of
      TBS on depressive symptomatology, brain function (e.g. functional MRI, PET, and qEEG),
      peripheral biomarkers (e.g. candidate genetic expression, neuroendocrine, inflammation, and
      neurotransmissions) in MDD patients.
    
  